NBC News (8/16, Lovelace) reports that new research indicates Eisai’s Leqembi (lecanemab) and Biogen’s Aduhelm (aducanumab), the first drugs meant to slow the progression of Alzheimer’s disease, “may only be available to a tiny fraction of patients.” The drugs “are approved for older adults with mild cognitive impairment or early-stage Alzheimer’s disease but, according to the study, less than 1 in 10 patients at this point in the disease may be prescribed them.” The findings were published in the journal Neurology.
Related Links:
— “Few patients may qualify to get new Alzheimer’s drugs, study suggests,” Berkeley Lovelace Jr., NBC News, August 16, 2023